Pharma BD Deal Intelligence
A $625M patent settlement plus ongoing royalties that let Merck keep selling Keytruda—now the world's top-selling drug at $25B+ annually. BMS and Ono held foundational PD-1 IP, but the settlement freed Merck to build the most broadly indicated cancer therapy ever developed.
Merck pays $625M to settle patent battle with Bristol-Myers Squibb and Ono over PD-1 antibody Keytruda intellectual property rights
Merck announces settlement and license agreement resolving Keytruda pembrolizumab patent litigation with BMS and Ono for $625 million
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Merck settled patent litigation with BMS and Ono Pharmaceutical over Keytruda (pembrolizumab) by paying $625M upfront plus ongoing royalties on worldwide Keytruda sales. The settlement resolved disputes over anti-PD-1 antibody intellectual property, enabling Merck to continue marketing Keytruda, which became the world's top-selling drug exceeding $25B in annual sales.
First-line advanced NSCLC is an immuno-oncology duopoly with Keytruda (pembrolizumab, Merck) as the clear anchor, generating $29.5B in 2024 worldwide sales per Merck's 10-K with NSCLC the single largest contributing indication. Anti-PD-1 mAbs (direct competitor class): Opdivo (nivolumab, BMS) holds non-squamous and squamous 2L monotherapy plus the Opdivo+Yervoy chemo-limited regimen in 1L (CheckMate-9LA, -227); Libtayo (cemiplimab, Regeneron/Sanofi) is approved in PD-L1-high monotherapy. Anti-PD-L1 mAbs: Tecentriq (atezolizumab, Roche) is approved in 1L combinations (IMpower150) and adjuvant resected stage II-IIIA; Imfinzi (durvalumab, AstraZeneca) dominates unresectable stage III post-chemoradiation (PACIFIC) and has 2024 global sales ~$4.7B across indications. CTLA-4 combinations: Imjudo (tremelimumab) + Imfinzi received 1L metastatic NSCLC approval per POSEIDON. Targeted-therapy segment (separate from IO but competing for patient share): Tagrisso (osimertinib, AstraZeneca) dominates EGFR+, Alecensa/Lorbrena in ALK+, Krazati/Lumakras in KRAS G12C. Commercial threat assessment: Keytruda's 1L pembro+chemo regimen (KEYNOTE-189/407) remains the dominant global first-line choice across PD-L1 strata; biosimilar entry post-2028 LOE and emerging PD-1/VEGF bispecifics (ivonescimab, Summit/Akeso per HARMONi-2 Chinese registration) are the medium-term threats.
Merck paid $625M upfront plus ongoing royalties on worldwide Keytruda sales to BMS/Ono.
Keytruda became top-selling drug globally ($25B+ annual). Settlement enabled continued commercialization.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Bristol-Myers Squibb Company (this deal) | 2017 | $625M | 74 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2017 deals · Merck & Co. Inc. deals · Oncology deals